OA-14 Persistent bone marrow and imaging MRD negativity may guide the duration of lenalidomide maintenance following ASCT in patients with multiple myeloma

Panagiotis Malandrakis; Ioannis Ntanasis‐Stathopoulos; Ioannis V. Kostopoulos; Maria Gavriatopoulou; Foteini Theodorakakou; Despina Fotiou; Magdalini Migkou; Μαρία Ρούσσου; Vassiliki Spiliopoulou; Evangelos Eleutherakis‐Papaiakovou; Efstathios Kastritis; Ourania Tsitsilonis; Meletios A Dimopoulos; Evangelos Terpos

doi:10.1016/s2152-2650(23)01581-1

Article2023

P861: PERSISTENT BONE MARROW AND IMAGING MRD NEGATIVITY AS CRITERIA TO STOP LENALIDOMIDE MAINTENANCE FOLLOWING ASCT: PRELIMINARY RESULTS OF A SINGLE-CENTER PROSPECTIVE COHORT STUDY

Panagiotis Malandrakis, Ioannis Ntanasis‐Stathopoulos, Ioannis V. Kostopoulos, Maria Gavriatopoulou, Foteini Theodorakakou, Despina Fotiou, Magdalini Migkou, Μαρία Ρούσσου, Vassiliki Spiliopoulou, Evangelos Eleutherakis‐Papaiakovou, Efstathios Kastritis, Ourania Tsitsiloni, Meletios A Dimopoulos, Evangelos Terpos

Article2024

Sustained MRD Negativity for Three Years Can Guide Discontinuation of Lenalidomide Maintenance after ASCT in Multiple Myeloma: Results from a Prospective Cohort Study

Panagiotis Malandrakis, Ioannis Ntanasis-Stathopoulos, Ioannis V. Kostopoulos, Vasiliki Spiliopoulou, Despina Fotiou, Foteini Theodorakakou, Magdalini Migkou, Nikolaos Kanellias, Evangelos Eleutherakis‐Papaiakovou, Efstathios Kastritis, Maria Gavriatopoulou, Ourania Tsitsilonis, Meletios A Dimopoulos, Evangelos Terpos

Article2022

P-051: Sustained bone marrow and imaging MRD negativity as indicators to discontinue lenalidomide maintenance after ASCT; preliminary results of a single-center prospective cohort study

Panagiotis Malandrakis, Ioannis Ntanasis‐Stathopoulos, Ioannis V. Kostopoulos, Maria Gavriatopoulou, Foteini Theodorakakou, Despina Fotiou, Magdalini Migkou, Μαρία Ρούσσου, Vassiliki Spiliopoulou, Evangelos Eleutherakis‐Papaiakovou, Efstathios Kastritis, Ourania Tsitsilonis, Meletios A Dimopoulos, Evangelos Terpos

Article2025

Sustained MRD negativity in patients with newly diagnosed multiple myeloma treated with carfilzomib-lenalidomide-dexamethasone with or without isatuximab (phase III IsKia trial).

Francesca Gay, Wilfried Roeloffzen, Meletios A Dimopoulos, Laura Rosiñol, Marjolein van der Klift, Albert Oriol, Eirini Katodritou, Ka-Lung Wu, Paula Rodríguez‐Otero, Roman Hájek, Elena M. van Leeuwen-Segarceanu, Elena Zamagni, Niels W.C.J. van de Donk, Katja Weisel, Fredrik Schjesvold, Joan Bladé, Hermann Einsele, Pieter Sonneveld, Mario Boccadoro, Annemiek Broijl

Article2005

Prognostic significance of magnetic resonance imaging of bone marrow in previously untreated patients with multiple myeloma

Lia A. Moulopoulos, Dimitra Gika, Αchilles Anagnostopoulos, Kay Delasalle, Diane Weber, Raymond Alexanian, Meletios A Dimopoulos

OA-14 Persistent bone marrow and imaging MRD negativity may guide the duration of lenalidomide maintenance following ASCT in patients with multiple myeloma

Discussion(0)

Related publications

P861: PERSISTENT BONE MARROW AND IMAGING MRD NEGATIVITY AS CRITERIA TO STOP LENALIDOMIDE MAINTENANCE FOLLOWING ASCT: PRELIMINARY RESULTS OF A SINGLE-CENTER PROSPECTIVE COHORT STUDY

Sustained MRD Negativity for Three Years Can Guide Discontinuation of Lenalidomide Maintenance after ASCT in Multiple Myeloma: Results from a Prospective Cohort Study

P-051: Sustained bone marrow and imaging MRD negativity as indicators to discontinue lenalidomide maintenance after ASCT; preliminary results of a single-center prospective cohort study

Sustained MRD negativity in patients with newly diagnosed multiple myeloma treated with carfilzomib-lenalidomide-dexamethasone with or without isatuximab (phase III IsKia trial).

Prognostic significance of magnetic resonance imaging of bone marrow in previously untreated patients with multiple myeloma